Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease
Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…Pre-formed fibrils injection worsen pathology caused by AAV-mediated over expression of α-synuclein
Objective: The overall goal is to produce a rat model of Parkinson's disease (PD), which reproduces progressive pathological changes, while displaying profound neuronal cell loss…The unfolded protein response pathway as a possible therapeutic target for the synucleinopathies
Objective: To investigate whether the pharmacological inhibition of unfolded protein response (UPR) pathway would be beneficial in cellular model of synucleinopathies. Background: It has been…Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein
Objective: We determined whether increased expression of DAT have an impact on the uptake of α-synuclein (αS). Background: The endocytosis of dopamine transporter (DAT) controls…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain
Objective: We aimed to analyze the influence of two microglia-related pathways on the accumulation of α-synuclein aggregates and neurodegeneration after intracerebral injection of sonicated murine…The systemic synuclein sampling study (S4)
Objective: The Systemic Synuclein Sampling Study (S4) is designed to characterize the distribution of alpha-synuclein (α-syn) pathology in multiple tissues and biofluids in Parkinson's disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.